Arexvy is accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk – GSK
GSK plc announced that the FDA has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged… read more.